| Market Cap | 1.38B | P/E | - | EPS this Y | 96.90% | Ern Qtrly Grth | - |
| Income | -170.36M | Forward P/E | -18.40 | EPS next Y | 65.00% | 50D Avg Chg | -4.00% |
| Sales | - | PEG | -0.10 | EPS past 5Y | - | 200D Avg Chg | 25.00% |
| Dividend | N/A | Price/Book | 5.39 | EPS next 5Y | 69.30% | 52W High Chg | -18.00% |
| Recommedations | 1.30 | Quick Ratio | 6.27 | Shares Outstanding | 47.33M | 52W Low Chg | 382.00% |
| Insider Own | 16.84% | ROA | -44.57% | Shares Float | 24.69M | Beta | - |
| Inst Own | 100.90% | ROE | -93.13% | Shares Shorted/Prior | 3.12M/2.76M | Price | 29.07 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 399,771 | Target Price | 38.88 |
| Oper. Margin | - | Earnings Date | - | Volume | 95,767 | Change | 2.00% |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. It has strategic alliance with Kite to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
| Stifel | Buy | Mar 14, 23 |
| HC Wainwright & Co. | Buy | Feb 13, 23 |
| Needham | Buy | Dec 12, 22 |
| Barclays | Overweight | Dec 12, 22 |
| Guggenheim | Buy | Oct 31, 22 |
| Needham | Buy | Oct 27, 22 |
| Canaccord Genuity | Buy | Jul 20, 22 |
| SVB Leerink | Outperform | Jun 23, 22 |
| SVB Leerink | Outperform | May 13, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Feb 07 | Sell | 30.77 | 6,966 | 214,344 | 15,589 | 02/09/23 |
| Heery Christopher | Chief Medical Office.. Chief Medical Officer | Feb 07 | Option | 0 | 22,555 | 22,555 | 02/09/23 | |
| Elghandour Rami | See Remarks See Remarks | Feb 07 | Sell | 30.77 | 31,442 | 967,470 | 38,769 | 02/09/23 |
| Elghandour Rami | See Remarks See Remarks | Feb 07 | Option | 0 | 70,211 | 70,211 | 02/09/23 | |
| SANDELL SCOTT D | 10% Owner 10% Owner | Dec 23 | Sell | 31.67 | 390 | 12,351 | 12/27/22 | |
| SANDELL SCOTT D | 10% Owner 10% Owner | Dec 20 | Sell | 30.74 | 179 | 5,502 | 12/22/22 | |
| New Enterprise Associates 15,... | 10% Owner 10% Owner | Jun 21 | Buy | 16.00 | 312,500 | 5,000,000 | 6,745,262 | 06/23/22 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner 10% Owner | Feb 08 | Buy | 15 | 1,666,667 | 25,000,005 | 2,033,196 | 02/10/22 |
| New Enterprise Associates 15,... | 10% Owner 10% Owner | Feb 08 | Buy | 15 | 1,583,333 | 23,749,995 | 6,432,762 | 02/09/22 |
| Carroll Jill | Director Director | Feb 08 | Buy | 15 | 1,666,667 | 25,000,005 | 2,033,196 | 02/09/22 |
| Novo Holdings A/S | 10% Owner 10% Owner | Feb 08 | Buy | 15 | 833,333 | 12,499,995 | 4,016,878 | 02/09/22 |